Do analysts rate GENB or PRTC?

Generate Biomedicines currently has a consensus target price of $25.40, indicating a potential upside of 77.13%. Given Generate Biomedicines' stronger consensus rating and higher possible upside, analysts plainly believe Generate Biomedicines is more favorable than PureTech Health. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Generate Biomedicines 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86 PureTech Health 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation and earnings, GENB or PRTC?

PureTech Health has lower revenue, but higher earnings than Generate Biomedicines. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Generate Biomedicines $30.30M 60.67 -$137.17M -$1.07 N/A PureTech Health $4.66M 91.01 -$109.74M N/A N/A

Is GENB or PRTC more profitable?

Company Net Margins Return on Equity Return on Assets Generate Biomedicines N/A N/A N/A PureTech Health N/A N/A N/A

Do analysts recommend ZYME or PRTC?

Zymeworks currently has a consensus price target of $37.33, suggesting a potential upside of 71.18%. Given Zymeworks' stronger consensus rating and higher possible upside, equities research analysts plainly believe Zymeworks is more favorable than PureTech Health. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zymeworks 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.82 PureTech Health 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, ZYME or PRTC?

Zymeworks has higher revenue and earnings than PureTech Health. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zymeworks $105.96M 15.03 -$81.13M -$1.37 N/A PureTech Health $4.66M 91.01 -$109.74M N/A N/A

Do analysts recommend SRPT or PRTC?

Sarepta Therapeutics presently has a consensus price target of $24.72, indicating a potential upside of 55.68%. Given Sarepta Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Sarepta Therapeutics is more favorable than PureTech Health. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sarepta Therapeutics 6 Sell rating(s) 6 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.14 PureTech Health 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, SRPT or PRTC?

PureTech Health has lower revenue, but higher earnings than Sarepta Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sarepta Therapeutics $2.20B 0.76 -$713.41M -$0.96 N/A PureTech Health $4.66M 91.01 -$109.74M N/A N/A

Do analysts prefer BHC or PRTC?

Bausch Health Cos presently has a consensus price target of $8.00, suggesting a potential upside of 14.19%. Given Bausch Health Cos' stronger consensus rating and higher probable upside, equities analysts plainly believe Bausch Health Cos is more favorable than PureTech Health. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bausch Health Cos 2 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.71 PureTech Health 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings and valuation, BHC or PRTC?

Bausch Health Cos has higher revenue and earnings than PureTech Health. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bausch Health Cos $10.85B 0.24 $157M -$2.96 N/A PureTech Health $4.66M 91.01 -$109.74M N/A N/A

Do analysts prefer PRTC or ABCL?

AbCellera Biologics has a consensus price target of $8.00, indicating a potential upside of 37.22%. Given AbCellera Biologics' stronger consensus rating and higher possible upside, analysts plainly believe AbCellera Biologics is more favorable than PureTech Health. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PureTech Health 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 AbCellera Biologics 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.67

Which has stronger earnings & valuation, PRTC or ABCL?

PureTech Health has higher earnings, but lower revenue than AbCellera Biologics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PureTech Health $4.66M 91.01 -$109.74M N/A N/A AbCellera Biologics $79.21M 22.48 -$146.41M -$0.48 N/A

PureTech Health (PRTC) Competitors

$17.42 0.00 (0.00%)

As of 07/31/2026

Compare

PRTC vs. GENB, ZYME, SRPT, BHC, and ABCL

Should you buy PureTech Health stock or one of its competitors? MarketBeat compares PureTech Health with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with PureTech Health include Generate Biomedicines (GENB), Zymeworks (ZYME), Sarepta Therapeutics (SRPT), Bausch Health Cos (BHC), and AbCellera Biologics (ABCL).

How does PureTech Health compare to Generate Biomedicines?

Generate Biomedicines (NASDAQ:GENB) and PureTech Health (NASDAQ:PRTC) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, media sentiment, analyst recommendations, profitability, risk and dividends.

Generate Biomedicines currently has a consensus target price of $25.40, indicating a potential upside of 77.13%. Given Generate Biomedicines' stronger consensus rating and higher possible upside, analysts plainly believe Generate Biomedicines is more favorable than PureTech Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Generate Biomedicines	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86
PureTech Health	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

PureTech Health has lower revenue, but higher earnings than Generate Biomedicines.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Generate Biomedicines	$30.30M	60.67	-$137.17M	-$1.07	N/A
PureTech Health	$4.66M	91.01	-$109.74M	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
Generate Biomedicines	N/A	N/A	N/A
PureTech Health	N/A	N/A	N/A

In the previous week, Generate Biomedicines had 2 more articles in the media than PureTech Health. MarketBeat recorded 2 mentions for Generate Biomedicines and 0 mentions for PureTech Health. Generate Biomedicines' average media sentiment score of 0.00 equaled PureTech Health'saverage media sentiment score.

Company	Overall Sentiment
Generate Biomedicines	Neutral
PureTech Health	Neutral

0.0% of PureTech Health shares are owned by institutional investors. 5.3% of PureTech Health shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Generate Biomedicines beats PureTech Health on 5 of the 9 factors compared between the two stocks.

How does PureTech Health compare to Zymeworks?

Zymeworks (NASDAQ:ZYME) and PureTech Health (NASDAQ:PRTC) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, risk, valuation, institutional ownership and analyst recommendations.

92.9% of Zymeworks shares are held by institutional investors. Comparatively, 0.0% of PureTech Health shares are held by institutional investors. 33.5% of Zymeworks shares are held by company insiders. Comparatively, 5.3% of PureTech Health shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Zymeworks currently has a consensus price target of $37.33, suggesting a potential upside of 71.18%. Given Zymeworks' stronger consensus rating and higher possible upside, equities research analysts plainly believe Zymeworks is more favorable than PureTech Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zymeworks	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
PureTech Health	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

PureTech Health has a net margin of 0.00% compared to Zymeworks' net margin of -126.92%. PureTech Health's return on equity of 0.00% beat Zymeworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zymeworks	-126.92%	-37.97%	-25.31%
PureTech Health	N/A	N/A	N/A

In the previous week, Zymeworks had 6 more articles in the media than PureTech Health. MarketBeat recorded 6 mentions for Zymeworks and 0 mentions for PureTech Health. Zymeworks' average media sentiment score of 1.13 beat PureTech Health's score of 0.00 indicating that Zymeworks is being referred to more favorably in the media.

Company	Overall Sentiment
Zymeworks	Positive
PureTech Health	Neutral

Zymeworks has a beta of 1.15, meaning that its share price is 15% more volatile than the broader market. Comparatively, PureTech Health has a beta of 1.15, meaning that its share price is 15% more volatile than the broader market.

Zymeworks has higher revenue and earnings than PureTech Health.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zymeworks	$105.96M	15.03	-$81.13M	-$1.37	N/A
PureTech Health	$4.66M	91.01	-$109.74M	N/A	N/A

Summary

Zymeworks beats PureTech Health on 10 of the 14 factors compared between the two stocks.

How does PureTech Health compare to Sarepta Therapeutics?

Sarepta Therapeutics (NASDAQ:SRPT) and PureTech Health (NASDAQ:PRTC) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, earnings, valuation, profitability, media sentiment and dividends.

Sarepta Therapeutics presently has a consensus price target of $24.72, indicating a potential upside of 55.68%. Given Sarepta Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Sarepta Therapeutics is more favorable than PureTech Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sarepta Therapeutics	6 Sell rating(s)	6 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.14
PureTech Health	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Sarepta Therapeutics has a beta of 0.24, meaning that its stock price is 76% less volatile than the broader market. Comparatively, PureTech Health has a beta of 1.15, meaning that its stock price is 15% more volatile than the broader market.

PureTech Health has lower revenue, but higher earnings than Sarepta Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sarepta Therapeutics	$2.20B	0.76	-$713.41M	-$0.96	N/A
PureTech Health	$4.66M	91.01	-$109.74M	N/A	N/A

86.7% of Sarepta Therapeutics shares are owned by institutional investors. Comparatively, 0.0% of PureTech Health shares are owned by institutional investors. 6.9% of Sarepta Therapeutics shares are owned by insiders. Comparatively, 5.3% of PureTech Health shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Sarepta Therapeutics had 11 more articles in the media than PureTech Health. MarketBeat recorded 11 mentions for Sarepta Therapeutics and 0 mentions for PureTech Health. Sarepta Therapeutics' average media sentiment score of 0.69 beat PureTech Health's score of 0.00 indicating that Sarepta Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Sarepta Therapeutics	Positive
PureTech Health	Neutral

PureTech Health has a net margin of 0.00% compared to Sarepta Therapeutics' net margin of -2.94%. Sarepta Therapeutics' return on equity of 7.56% beat PureTech Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sarepta Therapeutics	-2.94%	7.56%	2.94%
PureTech Health	N/A	N/A	N/A

Summary

Sarepta Therapeutics beats PureTech Health on 10 of the 14 factors compared between the two stocks.

How does PureTech Health compare to Bausch Health Cos?

Bausch Health Cos (NYSE:BHC) and PureTech Health (NASDAQ:PRTC) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, earnings, media sentiment, profitability, analyst recommendations, institutional ownership and valuation.

Bausch Health Cos has higher revenue and earnings than PureTech Health.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch Health Cos	$10.85B	0.24	$157M	-$2.96	N/A
PureTech Health	$4.66M	91.01	-$109.74M	N/A	N/A

In the previous week, Bausch Health Cos had 30 more articles in the media than PureTech Health. MarketBeat recorded 30 mentions for Bausch Health Cos and 0 mentions for PureTech Health. Bausch Health Cos' average media sentiment score of 0.33 beat PureTech Health's score of 0.00 indicating that Bausch Health Cos is being referred to more favorably in the media.

Company	Overall Sentiment
Bausch Health Cos	Neutral
PureTech Health	Neutral

Bausch Health Cos presently has a consensus price target of $8.00, suggesting a potential upside of 14.19%. Given Bausch Health Cos' stronger consensus rating and higher probable upside, equities analysts plainly believe Bausch Health Cos is more favorable than PureTech Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch Health Cos	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71
PureTech Health	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

PureTech Health has a net margin of 0.00% compared to Bausch Health Cos' net margin of -10.12%. PureTech Health's return on equity of 0.00% beat Bausch Health Cos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bausch Health Cos	-10.12%	-561.95%	6.31%
PureTech Health	N/A	N/A	N/A

Bausch Health Cos has a beta of 0.42, suggesting that its stock price is 58% less volatile than the broader market. Comparatively, PureTech Health has a beta of 1.15, suggesting that its stock price is 15% more volatile than the broader market.

78.7% of Bausch Health Cos shares are owned by institutional investors. Comparatively, 0.0% of PureTech Health shares are owned by institutional investors. 20.7% of Bausch Health Cos shares are owned by company insiders. Comparatively, 5.3% of PureTech Health shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Bausch Health Cos beats PureTech Health on 9 of the 13 factors compared between the two stocks.

How does PureTech Health compare to AbCellera Biologics?

PureTech Health (NASDAQ:PRTC) and AbCellera Biologics (NASDAQ:ABCL) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, profitability, dividends, risk and analyst recommendations.

PureTech Health has a beta of 1.15, meaning that its share price is 15% more volatile than the broader market. Comparatively, AbCellera Biologics has a beta of 1.14, meaning that its share price is 14% more volatile than the broader market.

In the previous week, AbCellera Biologics had 3 more articles in the media than PureTech Health. MarketBeat recorded 3 mentions for AbCellera Biologics and 0 mentions for PureTech Health. AbCellera Biologics' average media sentiment score of 0.13 beat PureTech Health's score of 0.00 indicating that AbCellera Biologics is being referred to more favorably in the news media.

Company	Overall Sentiment
PureTech Health	Neutral
AbCellera Biologics	Neutral

PureTech Health has higher earnings, but lower revenue than AbCellera Biologics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PureTech Health	$4.66M	91.01	-$109.74M	N/A	N/A
AbCellera Biologics	$79.21M	22.48	-$146.41M	-$0.48	N/A

AbCellera Biologics has a consensus price target of $8.00, indicating a potential upside of 37.22%. Given AbCellera Biologics' stronger consensus rating and higher possible upside, analysts plainly believe AbCellera Biologics is more favorable than PureTech Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PureTech Health	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
AbCellera Biologics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

PureTech Health has a net margin of 0.00% compared to AbCellera Biologics' net margin of -181.75%. PureTech Health's return on equity of 0.00% beat AbCellera Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PureTech Health	N/A	N/A	N/A
AbCellera Biologics	-181.75%	-14.86%	-10.62%

0.0% of PureTech Health shares are held by institutional investors. Comparatively, 61.4% of AbCellera Biologics shares are held by institutional investors. 5.3% of PureTech Health shares are held by company insiders. Comparatively, 28.4% of AbCellera Biologics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

AbCellera Biologics beats PureTech Health on 9 of the 15 factors compared between the two stocks.

Get PureTech Health News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PRTC vs. The Competition

Export

Metric	PureTech Health	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$424.04M	$3.51B	$6.81B	$12.69B
Dividend Yield	N/A	3.78%	2.59%	10.03%
P/E Ratio	N/A	7.34	281.03	25.13
Price / Sales	91.01	1,215.58	574.87	80.86
Price / Cash	N/A	44.80	28.64	34.82
Price / Book	1.38	16.89	11.03	6.21
Net Income	-$109.74M	-$12.54M	$3.48B	$347.60M
7 Day Performance	N/A	-0.63%	0.54%	0.88%
1 Month Performance	N/A	-7.39%	-4.19%	-3.62%
1 Year Performance	-8.75%	49.17%	63.11%	20.46%

PureTech Health Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PRTC PureTech Health	N/A	$17.42 flat	N/A	N/A	$424.04M	$4.66M	N/A	100
GENB Generate Biomedicines	1.6343 of 5 stars	$13.14 -3.9%	$25.40 +93.3%	N/A	$1.68B	$30.30M	N/A	312	High Trading Volume
ZYME Zymeworks	3.4294 of 5 stars	$22.61 -1.7%	$37.33 +65.1%	+74.5%	$1.68B	$105.96M	N/A	460	Positive News Upcoming Earnings
SRPT Sarepta Therapeutics	3.54 of 5 stars	$15.43 -2.9%	$24.72 +60.2%	-6.6%	$1.68B	$2.18B	N/A	1,372	Upcoming Earnings
BHC Bausch Health Cos	2.1058 of 5 stars	$4.53 +1.0%	$8.00 +76.8%	+20.8%	$1.68B	$10.27B	N/A	20,300	News Coverage Earnings Report Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PRTC) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PureTech Health (PRTC) Competitors

PRTC vs. GENB, ZYME, SRPT, BHC, and ABCL

How does PureTech Health compare to Generate Biomedicines?

Summary

How does PureTech Health compare to Zymeworks?

Summary

How does PureTech Health compare to Sarepta Therapeutics?

Summary

How does PureTech Health compare to Bausch Health Cos?

Summary

How does PureTech Health compare to AbCellera Biologics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRTC vs. The Competition

PureTech Health Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PureTech Health (PRTC) Competitors

PRTC vs. GENB, ZYME, SRPT, BHC, and ABCL

How does PureTech Health compare to Generate Biomedicines?

Do analysts rate GENB or PRTC?

Which has stronger valuation and earnings, GENB or PRTC?

Is GENB or PRTC more profitable?

Does the media prefer GENB or PRTC?

Do institutionals and insiders have more ownership in GENB or PRTC?

Summary

How does PureTech Health compare to Zymeworks?

Do insiders & institutionals hold more shares of ZYME or PRTC?

Do analysts recommend ZYME or PRTC?

Is ZYME or PRTC more profitable?

Does the media refer more to ZYME or PRTC?

Which has more volatility and risk, ZYME or PRTC?

Which has higher valuation and earnings, ZYME or PRTC?

Summary

How does PureTech Health compare to Sarepta Therapeutics?

Do analysts recommend SRPT or PRTC?

Which has more risk & volatility, SRPT or PRTC?

Which has higher valuation & earnings, SRPT or PRTC?

Do institutionals and insiders have more ownership in SRPT or PRTC?

Does the media prefer SRPT or PRTC?

Is SRPT or PRTC more profitable?

Summary

How does PureTech Health compare to Bausch Health Cos?

Which has stronger earnings and valuation, BHC or PRTC?

Does the media refer more to BHC or PRTC?

Do analysts prefer BHC or PRTC?

Is BHC or PRTC more profitable?

Which has more volatility & risk, BHC or PRTC?

Do institutionals & insiders hold more shares of BHC or PRTC?

Summary

How does PureTech Health compare to AbCellera Biologics?

Which has more risk and volatility, PRTC or ABCL?

Does the media prefer PRTC or ABCL?

Which has stronger earnings & valuation, PRTC or ABCL?

Do analysts prefer PRTC or ABCL?

Is PRTC or ABCL more profitable?

Do insiders & institutionals have more ownership in PRTC or ABCL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRTC vs. The Competition

PureTech Health Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools